Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2067 - Preclinical Characterization of IMAB362-vcMMAE, an Anti-CLDN18.2 Antibody–Drug Conjugate


11 Sep 2017


Poster display session


Clinical Research


Maria Kreuzberg


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


M. Kreuzberg1, R. Mitnacht-Kraus2, U. Sahin3, Ö. Türeci2

Author affiliations

  • 1 Ganymed Pharmaceuticals, AG, 55131 - Mainz/DE
  • 2 Ganymed Pharmaceuticals, AG, Mainz/DE
  • 3 Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz/DE


Abstract 2067


Antibody–drug conjugates combine the specific targeting and antitumor activity of monoclonal antibodies with the potent cell killing activity of cytotoxic small molecule drugs. IMAB362 is a monoclonal antibody specific for the tight junction protein Claudin 18.2 (CLDN18.2). In normal tissue, CLDN18.2 is exclusively expressed in the gastric mucosa. In the context of malignant transformation, CLDN18.2 can be found in gastric tumors as well as tumors from organs that do not normally express CLDN18.2 (eg, pancreas). Preclinical characterization of IMAB362 conjugated to the antimitotic molecule, monomethyl auristatin E, with a valine–citrulline linker (IMAB362–vcMMAE) is presented here.


IMAB362–vcMMAE binding characteristics and internalization were assessed in CLDN18.2-expressing human cell lines. Cell viability and IMAB362–vcMMAE-mediated cytotoxic effects (direct and indirect [bystander]) were also assessed in CLDN18.2 in vitro models. Xenograft mouse models of pancreatic and gastric cancers were developed to assess the cytotoxic and antitumor effects of IMAB362–vcMMAE in vitro.


IMAB362–vcMMAE showed a slightly decreased relative binding affinity on CLDN18.2-transfected cells and cells that endogenously express CLDN18.2 compared with unconjugated IMAB362. In cell lines that internalized IMAB362–vcMMAE, cell viability was reduced by 45–90%; EC50 negatively correlated with CLDN18.2 expression level, with the lowest EC50 being


IMAB362–vcMMAE is a highly specific and potent antibody-drug conjugate against in vivo and in vitro models of gastric and pancreatic cancers.

Clinical trial identification

Legal entity responsible for the study

Ganymed Pharamaceuticals AG, A company of Astellas Pharma, Inc


Ganymed Pharamaceuticals AG, A company of Astellas Pharma, Inc


M. Kreuzberg: Emplyee of Ganymed Pharamceuticals AG, a company of Astellas Pharma, Inc. R. Mitnacht-Kraus: Employee of Ganymed Pharmaceuticals AG, a company of Astellas Pharma, Inc. In addition, Dr. Mitnacht-Kraus has a patent P-24PCT issued, a patent P-33PCT issued, a patent P-34PCT issued, and a patent P-36PCT issued. U. Sahin: Stock option owner, ex-shareholder and cofounder of Ganymed Pharmaceuticals AG and Founder/CEO/shareholder of Biontech Holding outside the submitted work. Dr. Sahin has several patents issued to this work that have been acquired by Astellas. Ö. Türeci: Stock option owner, ex-shareholder, cofounder & CEO of Ganymed Pharmaceuticals AG, has received consultancy fees from Astellas, and has several patents issued to this work that have been acquired by Astellas.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.